Decoy Therapeutics Inc (DCOY)

09:06 AM

Decoy Therapeutics names MIT professor as advisory board chair - Investing.com

09:06 AM

08:30 AM

Decoy Therapeutics names MIT professor as advisory board chair By Investing.com - Investing.com Australia

08:30 AM

08:15 AM

Press Release: Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board - Moomoo

08:15 AM

May 23, 2026

Decoy Therapeutics (DCOY) Surges 13.5%: Testing Key Resistance at $7.67Shared Trade Ideas - Newser

May 23, 2026

May 22, 2026

Decoy Therapeutics Inc. (DCOY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

May 22, 2026

May 22, 2026

DCOY Sets May 22 Vote, Puts Focus Back on Thinly Traded Stock - Bez Kabli

May 22, 2026

May 20, 2026

hVIVO to host capital markets day as it pitches broader clinical development role - Yahoo Finance UK

May 20, 2026

May 19, 2026

Decoy Therapeutics Sets 2026 Annual Shareholder Meeting Date - TipRanks

May 19, 2026

May 19, 2026

Decoy Therapeutics sets date for 2026 annual meeting and proposal deadlines - Investing.com Australia

May 19, 2026

May 18, 2026

Number of shareholders of Decoy Therapeutics Inc. – NASDAQ:DCOY - TradingView

May 18, 2026

May 15, 2026

Decoy Therapeutics outlines antiviral pipeline milestones By Investing.com - Investing.com Nigeria

May 15, 2026

May 10, 2026

Certain Restricted Stock Units of Decoy Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2026. - marketscreener.com

May 10, 2026

May 10, 2026

Certain Stock Options of Decoy Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2026. - marketscreener.com

May 10, 2026

May 10, 2026

1,051,782 Common Stock of Decoy Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2026. - marketscreener.com

May 10, 2026

May 09, 2026

Decoy Therapeutics Inc. 2026 Q1 10-Q Filing: Financial Results, Risk Factors, and Forward-Looking Statements - Minichart

May 09, 2026

May 08, 2026

Decoy Therapeutics: Q1 Earnings Snapshot - KTEN

May 08, 2026

May 08, 2026

Decoy Therapeutics Inc. 1Q 2026: Net loss $(2.22M), EPS $(4.18) — 10-Q Summary - TradingView

May 08, 2026

May 08, 2026

Decoy Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 08, 2026

May 07, 2026

DCOY Q1'26 Earnings: EPS estimate is (4.12) USD - TradingView

May 07, 2026

May 02, 2026

Decoy Therapeutics to implement 1-for-12 reverse stock split - Investing.com

May 02, 2026

Apr 27, 2026

Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston - BioSpace

Apr 27, 2026

Apr 27, 2026

Decoy Therapeutics (DCOY) Proxy Filing Summary - Quartr

Apr 27, 2026

Apr 27, 2026

Decoy Therapeutics Inc (FRA:FP11) Stock PDF (Updated: 2026/04/27) - GuruFocus

Apr 27, 2026

Apr 27, 2026

Decoy Therapeutics Showcases Novel Antiviral Therapies in Boston - Intellectia AI

Apr 27, 2026

Apr 27, 2026

Decoy Therapeutics Inc (FRA:FP11) Stock Earnings Transcripts - GuruFocus

Apr 27, 2026

Apr 26, 2026

Salarius Pharmaceuticals stock tumbles after announcing $7 million discounted public offering - MSN

Apr 26, 2026

Apr 23, 2026

Is Decoy (DCOY) stock gaining market share | Q3 2024: EPS Tops ViewsHot Market Picks - Cổng thông tin điện tử tỉnh Lào Cai

Apr 23, 2026

Apr 10, 2026

DCOY Price Today: Decoy Therapeutics Inc. Stock Price, Quote & Chart - MEXC

Apr 10, 2026

Apr 10, 2026

Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline - BioSpace

Apr 10, 2026

Apr 09, 2026

Transcript : Decoy Therapeutics Inc.Special Call - marketscreener.com

Apr 09, 2026

Apr 09, 2026

CEO Rick Pierce to outline Decoy's 2026 outlook in April 9 webcast - Stock Titan

Apr 09, 2026

Apr 09, 2026

Decoy Therapeutics outlines antiviral pipeline milestones - Investing.com

Apr 09, 2026

Apr 09, 2026

Decoy Therapeutics Launches Multi-Virus Antiviral Platform - Intellectia AI

Apr 09, 2026

Apr 09, 2026

12 Health Care Stocks Moving In Tuesday's After-Market Session - Sahm

Apr 09, 2026

Apr 08, 2026

What is the volatility of Decoy (DCOY) Stock | Price at $5.84, Down 0.76%Expert Momentum Signals - Newser

Apr 08, 2026

Apr 07, 2026

DCOY Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 07, 2026

Apr 06, 2026

Decoy Therapeutics to Participate in Virtual Investor Closing Be - GuruFocus

Apr 06, 2026

Apr 06, 2026

Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026 - Finviz

Apr 06, 2026

Apr 06, 2026

Is Decoy (DCOY) Stock a Buy Now | DCOY Q4 Earnings: Beats Estimates by $25.32Expert Entry Points - Newser

Apr 06, 2026

Apr 03, 2026

Decoy Therapeutics Inc (STU:FP11) Stock Earnings Transcripts - GuruFocus

Apr 03, 2026

Apr 03, 2026

Decoy Therapeutics Inc (STU:FP11) Stock Price & 30 Year Financial Data - GuruFocus

Apr 03, 2026

Apr 03, 2026

Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - Bitget

Apr 03, 2026

Apr 03, 2026

DCOY Stock Analysis: Decoy Therapeutics Inc. Slides 7.5% to $5.8 Key Biotech Trends - Newser

Apr 03, 2026

Apr 02, 2026

Decoy Therapeutics regains Nasdaq minimum bid price compliance By Investing.com - Investing.com Australia

Apr 02, 2026